BIO-TECHNE 8-K: Officer/Director Changes or Comp Arrangements
Ticker: TECH · Form: 8-K · Filed: Jan 8, 2024 · CIK: 842023
| Field | Detail |
|---|---|
| Company | Bio-Techne Corp (TECH) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $550,000, $950,000, $475,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensatory-arrangements, corporate-governance
TL;DR
**BIO-TECHNE filed an 8-K on Jan 5, signaling potential executive changes or compensation shifts.**
AI Summary
BIO-TECHNE Corporation filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024. This filing indicates a change in compensatory arrangements for certain officers, or a departure/election of directors/officers, or other significant events. While the specific details of the event are not fully disclosed in this excerpt, such filings are crucial for investors as they signal potential shifts in leadership or executive compensation, which can impact company strategy and financial performance.
Why It Matters
Changes in leadership or executive compensation can signal strategic shifts or financial health, directly influencing investor confidence and the company's future direction.
Risk Assessment
Risk Level: medium — The filing indicates potential changes in leadership or compensation, which can introduce uncertainty regarding future company performance and strategy.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the changes in officers, directors, or compensatory arrangements, as these details will clarify the impact on BIO-TECHNE's strategic direction and financial outlook.
Key Players & Entities
- BIO-TECHNE Corporation (company) — the registrant filing the 8-K
- January 5, 2024 (date) — date of the earliest event reported
- January 8, 2024 (date) — date the 8-K was filed
- 0-17272 (dollar_amount) — Commission File Number
- 41-1427402 (dollar_amount) — I.R.S. Employer Identification Number
FAQ
What is the purpose of this 8-K filing by BIO-TECHNE Corporation?
This 8-K filing by BIO-TECHNE Corporation, filed on January 8, 2024, reports an event that occurred on January 5, 2024, falling under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 7.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits).
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 5, 2024, as stated in the 'Date of Report (Date of earliest event reported): January 5, 2024'.
What is BIO-TECHNE Corporation's trading symbol and on which exchange is it registered?
BIO-TECHNE Corporation's trading symbol is 'TECH' and it is registered on the NASDAQ exchange, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address of BIO-TECHNE Corporation?
The business address of BIO-TECHNE Corporation is 614 McKinley Place NE, Minneapolis, Minnesota 55413, with a telephone number of (612) 379-8854.
Under which specific items of Form 8-K is this filing categorized?
This filing is categorized under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 7.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits).
Filing Stats: 1,116 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2024-01-08 06:32:53
Key Financial Figures
- $550,000 — t provides for an annual base salary of $550,000, which will be annualized for the porti
- $950,000 — units grant with a grant date value of $950,000 pursuant to the Company's 2020 Equity I
- $475,000 — ith a grant date value of approximately $475,000, and (iii) performance-based restricted
Filing Documents
- tmb-20240105x8k.htm (8-K) — 48KB
- tmb-20240105xex10d1.htm (EX-10.1) — 111KB
- tmb-20240105xex99d1.htm (EX-99.1) — 5KB
- 0001558370-24-000125.txt ( ) — 308KB
- tmb-20240105.xsd (EX-101.SCH) — 3KB
- tmb-20240105_lab.xml (EX-101.LAB) — 15KB
- tmb-20240105_pre.xml (EX-101.PRE) — 11KB
- tmb-20240105x8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on January 5, 2024 is attached hereto as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits Exhibit No. Description 10.1 Executive Employment Agreement, dated January 4, 2024, between the Company and Matthew McManus 99.1 Press Release, dated January 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-TECHNE CORPORATION Date: January 8, 2024 By: /s/ Shane V. Bohnen Shane V. Bohnen Senior Vice President, General Counsel and Corporate Secretary